Kevin S. Boyle's Insider Trades & SAST Disclosures

Kevin S. Boyle's most recent trade in Alaunos Therapeutics Inc was a trade of 1,800,000 Employee Stock Option (right to buy) done . Disclosure was reported to the exchange on March 15, 2023.

Share

Note

This is a custom search result for pattern Kevin S. Boyle.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.

All Superstars

"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches "Balanced Fund" but not "Balanced Growth Fund" Balanced Fund: Use this format without quotation marks to search for all funds related to the term "Balanced Fund" The results may include "Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".

Stock	Client Name	Client Category	Action	Reported to Exchange	Quantity	Post Transaction Holding	Traded %	Avg. Price	Value	Security Type
Alaunos Therapeutics Inc 5-year high High Loss High Volume	Kevin S. Boyle	Director, Chief Executive Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	15 Mar 2023	1,800,000	1,800,000	-		-	Employee Stock Option (right to buy)
Alaunos Therapeutics Inc 5-year high High Loss High Volume	Kevin S. Boyle	Director, Chief Executive Officer	Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.41 per share.	30 Aug 2022	18,750	866,250 (0%)	0%	2.4	45,188	Common Stock
Alaunos Therapeutics Inc 5-year high High Loss High Volume	Kevin S. Boyle	Director, Chief Executive Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	30 Mar 2022	2,000,000	2,000,000	-		-	Employee Stock Option (right to buy)
Alaunos Therapeutics Inc 5-year high High Loss High Volume	Kevin S. Boyle	Director, Chief Executive Officer	Purchase of securities on an exchange or from another person at price $ 1.40 per share.	16 Nov 2021	9,116	885,000 (0%)	0%	1.4	12,762	Common Stock
Alaunos Therapeutics Inc 5-year high High Loss High Volume	Kevin S. Boyle	Director, Chief Executive Officer	Purchase of securities on an exchange or from another person at price $ 1.40 per share.	16 Nov 2021	884	875,884 (0%)	0%	1.4	1,238	Common Stock
Alaunos Therapeutics Inc 5-year high High Loss High Volume	Kevin S. Boyle	Director, Chief Executive Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	30 Aug 2021	2,625,000	2,625,000	-		-	Employee Stock Option (right to buy)
Alaunos Therapeutics Inc 5-year high High Loss High Volume	Kevin S. Boyle	Director, Chief Executive Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	30 Aug 2021	875,000	875,000 (0%)	0%		0	Common Stock

*All Values are in $ Million

Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures

Data as reported to USA Exchanges

View All The Insider Trades